Endo in Agreement with U.S. Government to Support Production of Critical Medicines

Date Published11/17/2021
Author NameMichael Dabaie
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Par Sterile Products LLC
Parent companyEndo International PLC
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2021
Domestically, the work will be done:In-house
Capital investment ($):120
Country(ies) from which reshored:Ireland
City reshored to:Rochester
State(s) reshored to:MI
If relevant, work nearshored to:-
Product(s) reshoredsterile fill-finish for pharma
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Government Incentives, covid-19
Government Incentive dollar amount:$90 million
Find Reshoring Articles